单位：[1]Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China内科学系风湿免疫内科华中科技大学同济医学院附属同济医院[2]Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China放射科华中科技大学同济医学院附属同济医院
This work was supported by grants from the National Natural Science
Foundation of China (81974254, 81901651 and 82270903) and Tongji Hospital
Clinical Research Flagship Program (No. 2019CR206).
第一作者单位：[1]Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
通讯作者：
通讯机构：[1]Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China[*1]Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
推荐引用方式(GB/T 7714)：
Cai Shaozhe,Hu Ziwei,Chen Yu,et al.BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept[J].ANNALS OF THE RHEUMATIC DISEASES.2023,82(6):881-883.doi:10.1136/ard-2022-223529.
APA：
Cai Shaozhe,Hu Ziwei,Chen Yu,Chen Yuxue,Ming Bingxia...&Dong Lingli.(2023).BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.ANNALS OF THE RHEUMATIC DISEASES,82,(6)
MLA：
Cai Shaozhe,et al."BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept".ANNALS OF THE RHEUMATIC DISEASES 82..6(2023):881-883
医学